Article Versions Notes

Kepka S, Cordeanu E-M, Zarca K, Frantz A-S, Ohlmann P, Andres E, Bilbault P, Durand-Zaleski I, Stephan D. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. Medicina. 2023; 59(1):181. https://doi.org/10.3390/medicina59010181

Kepka, Sabrina, Elena-Mihaela Cordeanu, Kevin Zarca, Anne-Sophie Frantz, Patrick Ohlmann, Emmanuel Andres, Pascal Bilbault, Isabelle Durand-Zaleski, and Dominique Stephan. 2023. "A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry" Medicina 59, no. 1: 181. https://doi.org/10.3390/medicina59010181

Kepka, S., Cordeanu, E.-M., Zarca, K., Frantz, A.-S., Ohlmann, P., Andres, E., Bilbault, P., Durand-Zaleski, I., & Stephan, D. (2023). A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. Medicina, 59(1), 181. https://doi.org/10.3390/medicina59010181